Denise Bannister, MD
Internal Medicine · Richardson, TXNPI 1326059130
Payments from drug & device makers
Across 386 payments — averaging $14.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$698
- GSK$417
- Otsuka America Pharmaceutical, Inc.$368
- Lilly USA, LLC$341
- Pfizer$334
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,734100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 91 | $1,165 |
| AbbVie(2 entities) | 42 | $698 |
| GSK | 29 | $417 |
| Otsuka America Pharmaceutical, Inc. | 21 | $368 |
| Lilly USA, LLC | 26 | $341 |
| Pfizer | 19 | $334 |
| AstraZeneca | 11 | $228 |
| Boehringer Ingelheim | 15 | $213 |
| Amarin Pharma, Inc. | 12 | $205 |
| Amgen | 12 | $196 |
| Radius Health, Inc. | 11 | $196 |
| Merck | 17 | $192 |
| Amneal Pharmaceuticals LLC | 11 | $177 |
| Sanofi-aventis U.S. LLC | 11 | $152 |
| Eisai Inc. | 6 | $87 |
| Johnson & Johnson | 7 | $86 |
| Astellas Pharma US Inc | 5 | $81 |
| Endo Pharmaceuticals Inc. | 4 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $65 |
| Currax Pharmaceuticals LLC | 4 | $58 |
| Genentech USA, Inc. | 3 | $51 |
| Dexcom, Inc. | 3 | $51 |
| Exact Sciences | 3 | $48 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $22 |
| Abbott | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Alvogen Inc | 1 | $15 |
| Vivus LLC | 2 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $11 |
How this compares
$5,742 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 47 | $65,726 |
| JardianceEmpagliflozin | 57 | $53,168 |
| MounjaroTirzepatide | 38 | $49,345 |
| EliquisApixaban | 33 | $41,319 |
| SynjardyEmpagliflozin/Metformin Hcl | 19 | $24,248 |
| MyrbetriqMirabegron | 24 | $21,753 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $16,474 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $15,015 |
| TrulicityDulaglutide | 13 | $11,834 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $7,690 |
| XareltoRivaroxaban | 13 | $7,107 |
| Rosuvastatin Calcium | 299 | $4,629 |
| SynthroidLevothyroxine Sodium | 66 | $3,932 |
| VascepaIcosapent Ethyl | 11 | $3,750 |
| Rivastigmine | 12 | $2,674 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy | $213 | $77,41576 claims |
| Novo NordiskOzempic | $1,165 | $65,72647 claims |
| Lilly USA, LLCMounjaro, Trulicity | $341 | $61,18051 claims |
| PfizerEliquis | $334 | $41,31933 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $417 | $24,16429 claims |
| Astellas Pharma US IncMyrbetriq | $81 | $21,75324 claims |
| Johnson & JohnsonXarelto | $86 | $7,10713 claims |
| AbbVieSynthroid | $698 | $3,93266 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $177 | $2,418270 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Richardson
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.